CytoMed Therapeutics Statistics Share Statistics CytoMed Therapeutics has 11.73M
shares outstanding. The number of shares has increased by 8.75%
in one year.
Shares Outstanding 11.73M Shares Change (YoY) 8.75% Shares Change (QoQ) 8.75% Owned by Institutions (%) n/a Shares Floating 4.43M Failed to Deliver (FTD) Shares 3,369 FTD / Avg. Volume 25.21%
Short Selling Information The latest short interest is 42.85K, so 0.37% of the outstanding
shares have been sold short.
Short Interest 42.85K Short % of Shares Out 0.37% Short % of Float 1.23% Short Ratio (days to cover) 3.06
Valuation Ratios The PE ratio is -20.83 and the forward
PE ratio is null.
CytoMed Therapeutics's PEG ratio is
0.46.
PE Ratio -20.83 Forward PE n/a PS Ratio 754.46 Forward PS n/a PB Ratio 5.97 P/FCF Ratio -14.31 PEG Ratio 0.46
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for CytoMed Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 7.25,
with a Debt / Equity ratio of 0.07.
Current Ratio 7.25 Quick Ratio 7.25 Debt / Equity 0.07 Debt / EBITDA -0.26 Debt / FCF -0.17 Interest Coverage -172.79
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $1.21K Profits Per Employee $-43.79K Employee Count 43 Asset Turnover 0.01 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 29.03% in the
last 52 weeks. The beta is -0.36, so CytoMed Therapeutics's
price volatility has been lower than the market average.
Beta -0.36 52-Week Price Change 29.03% 50-Day Moving Average 1.91 200-Day Moving Average 2.33 Relative Strength Index (RSI) 51.91 Average Volume (20 Days) 13,363
Income Statement In the last 12 months, CytoMed Therapeutics had revenue of 52.01K
and earned -1.88M
in profits. Earnings per share was -0.16.
Revenue 52.01K Gross Profit -515.82K Operating Income -2.63M Net Income -1.88M EBITDA -1.79M EBIT -1.88M Earnings Per Share (EPS) -0.16
Full Income Statement Balance Sheet The company has 3.44M in cash and 463.25K in
debt, giving a net cash position of 2.98M.
Cash & Cash Equivalents 3.44M Total Debt 463.25K Net Cash 2.98M Retained Earnings -10.88M Total Assets 7.38M Working Capital 3.79M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -1.69M
and capital expenditures -1.05M, giving a free cash flow of -2.74M.
Operating Cash Flow -1.69M Capital Expenditures -1.05M Free Cash Flow -2.74M FCF Per Share -0.24
Full Cash Flow Statement Margins Gross margin is -991.86%, with operating and profit margins of -5049.84% and -3621.15%.
Gross Margin -991.86% Operating Margin -5049.84% Pretax Margin -3648.38% Profit Margin -3621.15% EBITDA Margin -3443.05% EBIT Margin -5049.84% FCF Margin -5273.24%
